CeriBell (NASDAQ:CBLL) Posts Earnings Results, Beats Estimates By $0.07 EPS

CeriBell (NASDAQ:CBLL - Get Free Report) announced its earnings results on Thursday. The company reported ($0.36) earnings per share for the quarter, topping the consensus estimate of ($0.43) by $0.07, Zacks reports. CeriBell updated its FY 2025 guidance to EPS.

CeriBell Stock Performance

Shares of NASDAQ:CBLL traded down $1.13 on Friday, hitting $15.97. 468,171 shares of the company's stock were exchanged, compared to its average volume of 272,942. CeriBell has a 1-year low of $10.01 and a 1-year high of $32.75. The stock's 50-day moving average is $18.06.

Analyst Upgrades and Downgrades

A number of research firms have recently weighed in on CBLL. LADENBURG THALM/SH SH started coverage on CeriBell in a research report on Friday, April 4th. They set a "buy" rating and a $32.00 price objective on the stock. Canaccord Genuity Group reaffirmed a "buy" rating and issued a $33.00 price target on shares of CeriBell in a research report on Wednesday, February 26th. Seven research analysts have rated the stock with a buy rating, According to MarketBeat.com, CeriBell presently has an average rating of "Buy" and a consensus target price of $32.50.

Insider Buying and Selling

In other CeriBell news, CEO Xingjuan Chao sold 15,628 shares of the firm's stock in a transaction that occurred on Wednesday, April 23rd. The shares were sold at an average price of $15.11, for a total transaction of $236,139.08. Following the sale, the chief executive officer now owns 727,151 shares of the company's stock, valued at approximately $10,987,251.61. This trade represents a 2.10 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders sold a total of 24,700 shares of company stock worth $372,434 over the last 90 days.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.